Why the study?
High-sensitivity cardiac troponin testing is promising for cardiovascular risk prediction, but whether serial testing can dynamically predict risk remains uncertain.
Does serial high-sensitivity cardiac troponin I testing dynamically predict the risk of cardiovascular death in the general population?
Does serial high-sensitivity cardiac troponin I testing dynamically predict the risk of cardiovascular death in the general population?
Serial high-sensitivity cardiac troponin I testing over time can dynamically track and predict the future risk of cardiovascular death in the general population.
Answers are grounded in this paper and cite their sources.
Serial hs-cTnI trends may refine CV death risk stratification in primary prevention; leaves open whether monitoring should guide interventions.
BACKGROUND: High-sensitivity cardiac troponin testing is a promising tool for cardiovascular risk prediction, but whether serial testing can dynamically predict risk is uncertain. We evaluated the trajectory of cardiac troponin I in the years prior to a cardiovascular event in the general population, and determine whether serial measurements could track risk within individuals. METHODS: In the Whitehall II cohort, high-sensitivity cardiac troponin I concentrations were measured on three occasions over a 15-year period. Time trajectories of troponin were constructed in those who died from cardiovascular disease compared to those who survived or died from other causes during follow up and these were externally validated in the HUNT Study. A joint model that adjusts for cardiovascular risk factors was used to estimate risk of cardiovascular death using serial troponin measurements. The joint model demonstrated an independent association between temporal evolution of troponin and risk of cardiovascular death (HR per doubling, 1.45, 95% CI,1.33-1.75). CONCLUSIONS: Cardiac troponin I concentrations increased in those dying from cardiovascular disease compared to those surviving or dying from other causes over the preceding decades. Serial cardiac troponin testing in the general population has potential to track future cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Kimenai et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: